Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Hepatocellular 1Ascites 1Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck 1

Interventions

Oxaliplatin 4Leucovorin 4Irinotecan 4Fluorouracil 4Capecitabine 3Bevacizumab 3cobimetinib 2Tomography, X-Ray Computed 2Surveys and Questionnaires 2Standard of Care 2Specimen Handling 2Panitumumab 2Magnetic Resonance Spectroscopy 2Ketamine 2Hydroxychloroquine 2Cyclophosphamide 2Cisplatin 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tivozanib 1sodium thiosulfate 1rucaparib 1romiplostim 1rilotumumab 1regorafenib 1pralsetinib 1ponatinib 1pembrolizumab 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastrointestinal Neoplasms × danvatirsen × Clear all
NCT02417753 2017-05-15

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
1 enrolled 10 charts
GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡